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a  b  s  t  r  a  c  t
In Argentina, there have been no studies aimed at establishing the prevalence of dysg-
lycaemia (impaired fasting glucose [IFG], impaired glucose tolerance [IGT] and diabetes
mellitus [DM]) in patients with chronic kidney disease (CKD). Our group decided to conduct
an  observational study to evaluate the frequency with oral glucose tolerance test (OGTT) in
CKD patients with no previous data for dysglycaemia in their medical records.
OGTT was performed in 254 patients (60.62% male) with stage 3, 4 and 5 CKD under
conservative treatment, haemodialysis or transplantation.
Rsults for DM were found in 10 patients according to fasting glucose alone (3.94%; 95%
CI:  1.35–6.53%), 11 patients with exclusively the second hour criterion (4.33%; 95% CI:
1.63–7.03%), 15 with both criteria (5.91%; 95% CI: 2.81–9.00%) and 36 patients with at least
one  criteria (14.17%; 95% CI: 9.69–18.66%). In a multivariate analysis, DM was associated with
waist circumference (OR = 1.033 per cm; 95% CI, 1.005 to 1.062; P = .019) and with conservative
treatment vs. replacement therapy (OR = 0.41; 95% CI: 0.19–0.92; P = .028). IGT was evident in
24.6% and 20.3 on conservative vs. replacement therapy, with no statistically signiﬁcant dif-
ference. IFG (ADA criteria) was 19.75 vs. 9.24% in conservative vs. replacement therapy, witha  statistically signiﬁcant difference.OGTT is suggested for all CKD patients since it is able to detect the full range of unknown
dysglycaemias, which avoids underdiagnoses and favours performing treatments to prevent
progression in DM risk groups (IFG and/or IGT). It also aids in the selection of the most
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appropriate medication for transplantation or treatment initiation in new cases of undiag-
nosed  DM to decrease morbidity and mortality.
© 2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Alteraciones  glucémicas  en  los  pacientes  con  enfermedad  renal  crónica
Palabras clave:
Prueba de tolerancia oral a la
glucosa
Enfermedad renal crónica
Diabetes
Glucemia alterada en ayunas
Tolerancia alterada a la glucosa
Hemodiálisis
Trasplante
r  e  s  u  m  e  n
En Argentina no se han realizado estudios destinados a establecer la prevalencia de dis-
glucemias (glucemia alterada en ayunas [GAA], tolerancia alterada a la glucosa [TAG] y
diabetes mellitus [DM]) en pacientes con enfermedad renal. Se decidió realizar un estudio
observacional, evaluando la frecuencia con prueba de tolerancia oral a glucosa (PTOG) en
pacientes con enfermedad renal crónica (ERC), sin registro de disglucemia en sus historias
clínicas.
Se  realizó PTOG a 254 pacientes (60,62% masculinos), con ERC estadios 3, 4 y 5, en tratamiento
conservador, hemodiálisis o trasplante.
Los resultados mostraron pacientes con valores de DM: 10 pacientes según ayunas exclusi-
vamente (3,94%; IC 95%: 1,35-6,53%); exclusivamente segunda hora, 11 pacientes (4,33%; IC
95%: 1,63-7,03%); por ambos criterios, 15 pacientes (5,91%; IC 95%: 2,81-9,00%); por al menos
un  criterio, 36 pacientes (14,17%; IC 95%: 9,69-18,66%). En análisis multivariado, la DM se aso-
ció  con valour de cintura (OR = 1,033 por cm; IC 95%: 1,005-1,062; p = 0,019) y con tratamiento
sustitutivo vs. conservador (OR = 0,41; IC 95%: 0,19-0,92; p = 0,028). La GAA (criterio ADA) fue
del  19,75% en tratamiento conservador vs. 9,24% en tratamiento sustitutivo, con diferencia
estadísticamente signiﬁcativa. No fue signiﬁcativa la diferencia de TAG que evidenció 24,6
y  20,3% en tratamiento conservador y sustitutivo, respectivamente.
Se  propone la realización de PTOG en todo paciente con ERC, ya que permite la detección de
todo  el rango de disglucemias desconocidas, evitando el subdiagnóstico y favoreciendo la
realización de tratamientos para evitar su progresión, en caso de estar ante la presencia de
un grupo de riesgo para DM (GAA o TAG), así como la elección de la medicación más adecuada
para el trasplante o el inicio del tratamiento de nuevos casos de DM no diagnosticada, para
disminuir la morbimortalidad.
© 2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-NDIntroduction
There are numerous studies in the general population1 on the
prevention of the development of diabetes mellitus (DM)2 and
its associated complications: renal and cardiovascular disease
and premature death.3 There has been less attention in study-
ing the metabolic abnormalities4 of chronic kidney disease
(CKD) patients without DM,  that may cause the development
of hyperglycaemia.
In addition to the typical changes of CKD (hyperparathy-
roidism, activation of the renin angiotensin system, anaemia,
vitamin D deﬁciency, inﬂammatory state, etc.) CKD is char-
acterised by reduced peripheral insulin sensitivity,5 reduced
insulin secretion,6 and changes in the levels of various sub-
stances such as leptin7,8 and cytokines. Such changes make
these patients susceptible to developing hyperglycaemia9 and
hypoglycaemia.10Recently, an alarming increase has been seen in the inci-
dence of post-transplant DM,  or new onset diabetes mellitus
after transplant (NODAT),11,12 with a prevalence of 25% in
some studies.13 However, there is limited knowledge on the(http://creativecommons.org/licenses/by-nc-nd/4.0/).
incidence of new cases of DM in patients with CKD await-
ing transplant.14 Based on some studies, it is suspected that
new cases of DM develop during haemodialysis (new onset
diabetes mellitus after dialysis [NODAD]).15 This phenomenon
has been conﬁrmed by other groups who also warned about
the ﬁnding,16 generating concern that these patients had been
underdiagnosed in earlier stages because their glycaemic lev-
els had improved with the onset of CKD.17
There are not protocols designed to DM detection in CKD
patients and there is no validation of the criteria used in the
general population for the use in CKD patients.
Conducting studies aiming to prevent new cases of DM by
identifying the presence of different glycaemic changes and
other risk factors in the different stages of CKD is challenging.
In Argentina, until now, there have been no studies that
aimed to establish the prevalence of dysglycaemia (taken
to mean impaired fasting blood glucose [IFG], impaired glu-
cose tolerance [IGT], or DM) in patients with CKD who  have
no history of DM as the underlying cause or a concomi-
tant condition in their clinical notes. Due to the lack of
prospective studies analayzing the prevalence and clinical
signiﬁcance of dysglycemia in CKD patients we  decided to
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onduct an observational study in CKD patients being classi-
ed according to the reccomendations of the National Kidney
oundation (NKF).3 Thus the frequency of dysglycaemia in
atients with no previous medical records of DM was evalu-
ted. We  used the protocol “Alteraciones metabólicas de pacientes
on enfermedad renal crónica (Metabolic Changes in Patients with
hronic Kidney Disease)” (AMPERC) of the Argentine Society of
ephrology. The aim was to evaluate CKD patients on conser-
ative treatment, CKD patiens on haemodialysis, or with renal
ransplant, the oral glucose tolerance test (OGTT) as described
y the WHO18 and relate the ﬁndings to risk factors. This
ethod of evaluation was chosen because previous obser-
ations had determined that evaluation of fasting samples
esults in under-diagnosis of glycaemic abnormalities.19,20
aterials  and  methods
ample,  inclusion  and  exclusion  criteria
he study included 254 patients (60.62% were male). The inclu-
ion criteria were as follows: patients with age ≥ 18 years; with
 diagnosis of CKD according to the NKF3; patients on either
onservative treatment, haemodialysis, or transplanted; no
reviously-diagnosed of blood glucose abnormalities; agree-
ent to undergo OGTT; and with no contraindication for OGTT
se; with signed informed consent form before undergoing
ny procedure speciﬁc to the study.
The exclusion criteria were: a previous diagnosis of DM,
GT, or IFG; on hypoglycaemics agents, insulin, corticosteroids,
r anabolic steroids; severe concomitant disease (that is, life
xpectancy less than 2 years); acute clinical events during
he 2 previous months (AMI, surgery, etc.); hypothyroidism;
iver disease; pregnancy or breast-feeding; patients following
nother investigation protocol with a speciﬁc intervention or
edication; and those that declined to undergo the glucose
oading test.
Consecutive patients with CKD (deﬁned according to NKF
riteria) on conservative treatment, treated in clinic from a
xed study start date were enrolled in the study. The diagno-
is of CKD had to be established more  than 3 months prior
o enrolment. The stages of CKD (≤60 mL/min/1.73 m2) were
ssessed using the abbreviated MDRD 4 formula.3
The study also included patients on haemodialysis or
ransplanted, for more  than 3 months prior to starting
he study and with no known history of glycaemia-related
isease.
The OGTT followed the following protocol: for 3 days prior
o the test, patients were instructed to follow a non restricted
iet, rich in carbohydrates containing alt least 150 g/day of car-
ohydrates. The test was carried out after 8 h of fasting, and
atients were instructed to refrain from tobacco for 24 h prior
o the test. Each patient had to remain at rest during the test.
n initial blood sample was taken (fasting, time 0), then, a
olution of 20% glucose was given (75 g glucose dissolved in
75 mL  of water acidulated with the juice of ¼ lemon). The
olution was ingested over a period of 5–10 min. One hundred
nd twenty minutes after igestion of the solution a second
lood sample was obtained. The diagnostic criteria for DM
ere the following: (a) fasting blood glucose higher than or(2):133–140 135
equal to 126 mg/dL, or (b) blood glucose at 120 min  higher than
or equal to 200 mg/dL. The cut-off points for the diagnosis of
IFG were based on the consideration of two guidelines: (a) the
ADA criteria, greater than or equal to 100 mg/dL; or (b) the
criteria followed by the Argentine Society of Diabetes21 and the
WHO,18 greater than or equal to 110 mg/dL. In both cases, the
upper limit for this category was 126 mg/dL; above this glucose
concentration patients were classiﬁed as having DM.  Patients
with values between 140 mg/dL and 200 mg/dL at 120 min  were
classiﬁed as having IGT.
The aetiology and duration of CKD were carefully doc-
umented, as well as the nature and starting date of
the treatment (conservative or replacement: haemodialy-
sis or renal transplant). Past medical history of systemic
hypertension (according to JNC criteria), arrhythmias, heart
failure, angina, or myocardial infarction, medications were
recorded. Past history of left ventricular hypertrophy and
cerebrovascular disease was also recorded. History of inter-
mittent claudication, leg ulcers, peripheral neuropathy,
retinopathy, cataracts, glaucoma, non-traumatic amputation,
gout or hyperuricaemia, hypercholesterolaemia, hypertriglyc-
eridaema, immune diseases (lupus, rheumatoid arthritis,
Hashimoto, other) neoplastic disease, HIV-AIDS, hepatitis A,
B, or C, tuberculosis, or active infectious diseases, was speciﬁ-
cally recorded. In women, history of gestational DM was noted.
The degree of physical activity, smoking habits, and alcohol
consumption were documented; drug addiction was speciﬁ-
cally investigated. As mentioned all medications being taken
at the time of entry to the study were also recorded. Family
history of renal disease, systemic hypertension, DM,  obesity,
cardiovascular events in men  <55 years and women <65 years
was noted.
On the day of study entry, the following clinical and para-
clinical data were collected: height in cm,  weight, estimated
“dry” weight in kg, waist and hip measurements in cm,  blood
pressure (mmHg), previous fasting blood glucose level, and
HbA1c if previously measured.
In addition, the values of haemoglobin level, leucocyte
count, serum creatinine, serum urea, total cholesterol, HDL
and LDL cholesterol, serum triglycerides, and intact parathy-
roid hormone (iPTH) level were also requested.
For the determination of body mass index, a calibrated
scale or electronic balance with an integrated or wall altimeter
was used. A wall altimeter consists of a rigid vertical surface
with an attached scale in centimetres and a horizontal mobile
surface at right angles, which slides freely vertically. The infe-
rior surface lies on the ﬂoor or on any supporting surface on
top of the ﬂoor, lying at the 0 of the measuring scale. The
subject must be able to stand, with their back to the vertical
surface so that their heels, buttocks and head are in contact
with it. The heels must be kept together and the shoulders
relaxed, to minimise misalignment of the spine. The head
must be kept such that the inferior border of the orbit is in
the same horizontal plane as the external auditory meatus
(Frankfurt plane); the hands must be free and relaxed. Each
patient was asked to take a deep breath, which relaxes the
shoulders, and to stretch upwards to make themselves as tall
as possible. Stretching minimises the variation in height that
occurs throughout the day, which can be up to 2 cm.  The hor-
izontal surface was then slid downwards, in contact with the
 0 1 6136  n e f r o l o g i a. 2
vertical plane, until it touched the subject’s head. The reading
was then taken from the scale (in centimetres).
For the determination of the waist circumference, or
perimeter, a calibrated ﬂexible steel tape measure was used, in
cm with increments in mm,  with a blank space of at least 3 cm
before the line that records zero. The patient had to remain
standing. The measurement was made in a horizontal plane,
at a distance midway between the inferior border of the last rib
and the iliac crest. Each of these points had to be palpated and
marked and the midway point marked with a tape measure.
When the legs were together with the buttocks relaxed, the
measurer placed themselves in front of the patient and mea-
sured at the height of the trochanter in line with the pubic
symphysis (this comprised the hip measurement in centime-
tres).
For blood pressure measurement, all the instruments
were validated and duly calibrated. All the instruments used
in the study were controlled against an instrument whose
accuracy and precision had been previously assessed. The per-
son responsible for the measurement of blood pressure was
trained in the standard technique, and patients had to be
adequately prepared and positioned. Patients had to remain
seated and at rest for at least 5 min  with their feet on the
ﬂoor, their back leaning against the chair back, with the arm
at the level of the heart. The recording was made at least
30 min  after any caffeine ingestion, exercise, or tobacco use.
The auscultatory method was used with aneroid and mer-
curial sphygmomanometers. To ensure accuracy, a cuff of
appropriate size had to be used, covering at least 50% of the
circumference of the arm, and 80% of its length. The midline
of the inﬂatable cuff was positioned over the brachial artery.
At least 2 measurements were taken to calculate the mean
recording. For manual measurements, the systolic blood pres-
sure was estimated by obliterating the radial pulse; in a second
step, the cuff was inﬂated 20 or 30 mmHg  above the level deter-
mined by auscultation.The speed of cuff deﬂation for the auscultatory measure-
ment was 2 mmHg/s. The systolic pressure was established
based on the ﬁrst of 2 or more  clear Korotkoff sounds (start of
phase 1); diastolic pressure was deﬁned by the disappearance
Table 1 – Anthropometric and metabolic characteristics of the s
Mean Standard deviati
Baseline blood glucose, mg/dL 95.37 18.89 
Blood glucose at 120 min, mg/dL 133.70 51.27 
HbA1c, % 5.56  0.52 
Height, m 164 10 
Weight, kg 72.33 15.66 
Waist, cm 91.47 14.07 
BMI, kg/m2 26.80 5.16 
Waist/height ratio 55.83 8.64 
Uric acid, mg/dL 6.63 1.82 
Total cholesterol, mg/dL 179.66 45.15 
HDL, mg/dL 46.47 15.84 
LDL, mg/dL 100.65 39.05 
Triglycerides, mg/dL 162.60 98.88 
iPTH, pg/mL 438.02 499.42 
BMI, body mass index; HbA1c, glycosylated haemoglobin; HDL, high densit
density lipoprotein cholesterol.;3 6(2):133–140
of the Korotkoff sounds (start of phase 5). In cases of arte-
rial stiffness causing blowing sounds until a value close to 0,
the value corresponding to the mufﬂing of the sounds was
recorded. For patients with vascular access, blood pressure
was  determined in the contralateral arm.
Statistical  analysis
The quantitative variables, except for clearance, are described
as mean ± standard deviation. The nature and distribu-
tion of the qualitative variables were analysed using the
Shapiro–Wilk test. A Chi-square test was used to compare
ratios; the comparison between 2 groups of quantitative data
with normal distribution was done using the Student t test
for independent samples. The differences between 3 groups
of data with normal distribution were determined using one-
way ANOVA (Scheffe post hoc test). In cases of abnormal
distribution, the Kruskal–Wallis test was used. To evaluate
the multivariate association between the presence of DM and
different independent covariates, multiple logistic regression
was used (quasi-Newton method for maximum likelihood). A
P-value <.05 was considered statistically signiﬁcant.
Results
The study included 100 women and 154 men, with a mean
age of 59.86 ± 17.23 years. The conservative treatment group
had 81 patients (46 men), the haemodialysis group had 140 (87
men), and the transplant group had 33 (21 men).
The anthropometric and general metabolic characteristics
are shown in Table 1.
Table 2 shows the differences recorded in variables between
patients on conservative treatment, on dialysis, or with trans-
plant.
Table 3 shows the prevalence of DM and DM risk groups
(IFG or IGT) in the whole sample.
The number of patients without DM according to any  of
the criteria used (fasting or 2 h after glucose loading) was
218 (85.82%); the number with DM according to the fasting
tudy popluation.
on Median 25th percentile 75th percentile
92.00 81.00 104.00
121.00 96.00 165.00
5.50 5.20 5.80
164 158 171
70.55 61.15 81.80
91.00 81.00 100.00
26.05 23.09 29.75
55.14 50.00 61.07
6.80 5.30 7.80
176.00 144.00 208.50
45.00 37.00 52.00
96.00 73.00 120.00
144.00 103.00 194.00
237.00 107.50 569.50
y lipoprotein cholesterol; iPTH intact parathyroid hormone; LDL, low
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Table 2 – Differences between conservative treatment, dialysis, and transplant groups.
Variable Conservative
treatment
[A]
(N  = 81)
Haemodialysis
[B]
(N  = 140)
Transplant
[C]
(N  = 33)
P-value
Mean (SD) Mean (SD) Mean (SD) A vs B B vs C C vs A
Age, years 67.84 (12.80) 58.64 (17.57) 46.91 (14.02) <0.01 <0.01 <0.01
Baseline blood glucose, mg/dL 105.49 (19.44) 90.83 (17.68) 93.62 (12.86) <0.01 NS <0.01
Blood glucose at 120 min, mg/dL 145.49 (59.29) 133.17 (47.81) 115.12 (46.58) NS NS <0.05
Previous baseline blood glucose, mg/dL 104.73 (13.74) 97.49 (20.18) 96.47 (10.50) NS NS <0.05
Height, m 1.67 (0.09) 1.64 (0.10) 1.64 (0.10) <0.05 NS <0.05
Weight, kg 79.14 (14.38) 69.97 (16.37) 65.75 (9.24) <0.01 <0.01 <0.01
Waist, cm 95.89 (14.34) 90.19 (14.50) 86.20 (9.34) <0.05 NS <0.05
Systolic blood pressure, mmHg 137.32 (22.12) 129.72 (25.78) 128.66 (24.09) <0.01 NS <0.01
Diastolic blood pressure, mmHg 92.23 (11.33) 89.85 (10.90) 89.03 (10.01) <0.05 NS <0.05
BMI, kg/m2 28.35 (4.27) 26.42 (5.55) 24.64 (4.49) <0.05 NS <0.05
Waist/height 57.48 (8.34) 55.61 (9.10) 52.79 (7.01) NS NS <0.05
Serum urea, mg/dL 6.65 (2.03) 6.91 (1.56) 5.93 (1.85) NS <0.05 <0.05
Serum cholesterol, mg/dL 204.13 (46.99) 164.31 (39.94) 201.22 (36.15) <0.01 <0.01 NS
HDL cholesterol, mg/dL 48.75 (18.34) 43.34 (11.76) 56.38 (21.86) <0.01 <0.01 NS
LDL cholesterol, mg/dL 123.81(41.98) 87.77 (33.70) 110.39 (28.62) <0.01 <0.01 NS
Serum triglycerides, mg/dL* 163.34 (81.73) 157.52 (112.96) 187.57 (86.07) NS NS NS
PTH, pg/mL* 136.06 (102.86) 545.36 (544.67) 117.49 (88.05) <0.01 <0.01 NS
∗ Kruskal–Wallis test.
Table 3 – Frequency of diabetes mellitus, impaired fasting blood glucose, and impaired glucose tolerance.
Number of patients Percentage (%)
Values consistent with DM according to fasting criterion only 10 3.9
Values consistent with DM according to 120 min criterion only 11  4.3
Values consistent with DM according to both criteria 15 5.9
Values consistent with impaired fasting blood glucose (ADA criterion) 32 12.6
Values consistent with impaired fasting blood glucose (SAD criterion) 18 7.1
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riterion only (without the 2 h criterion) was 10 (3.94%; 95% CI,
.35%–6.53%); the number with DM according to the 2 h cri-
erion only (without the fasting criterion) was 11 (4.33%, 95%
I, 1.63%–7.03%); the number with DM according to both crite-
ia was 15 (5.91%, 95% CI, 2.81%–9.00%), and the number of
atients with DM based on at least 1 criterion was 36 (14.17%,
5% CI, 9.69%–18.66%).
The frequency of DM differed according to the type of
reatment. Diabetes was more  common in individuals on
conservative treatment than in individuals on replacement
herapy: 23.45% vs 9.82%) (P = .001).
Likewise, the frequency of IFG (ADA criterion) differed
etween treatments: 19.75% in those treated conservatively
s 9.24% in patients on replacement therapy (P = .02). The fre-
uency of IGT was also higher in those treated conservatively
24.6% vs 20.23%) although the difference was not statistically
igniﬁcant (P = .521).
In the multivariate analysis by multiple logistic regres-
ion, having DM (using any of the accepted criteria) was
ssociated with the waist circumference value (OR = 1.033 per
entimetre; 95% CI, 1.005–1.062; P = .019) and with the type
f treatment, replacement vs conservative (OR = 0.41; 95% CI,
.19–0.92, P = .028). None of the other variables showed a sta-
istically signiﬁcant association.55 21.6
Discussion
The current criteria for blood glucose values for the diagnosis
of DM, which are based on the probability of develop-
ing retinopathy,22 and the criteria for IFG in the general
population23 have been modiﬁed several times in recent years.
To this day, IFG in the general population remains a subject of
debate, if we consider that different associations such as the
American Diabetes Association (ADA),24 and the WHO18 place
the cut-off value at 100 mg/dL and 110 mg/dL, respectively.
The 120 min  blood glucose level of the WHO-standardised glu-
cose loading test18 for the diagnosis of IGT and DM remains
unchanged. The difﬁculty with this classiﬁcation is the lack
of concordance between the two values (fasting and post-
loading) when it comes to identifying patients at risk of
developing DM and in the development of cardiovascular
disease.25 In 2010, the ADA added the use of standardised
glycosylated haemoglobin for the diagnosis of DM and its
intermediate stages.26
There is some information on the development of DM
20in patients with CKD on conservative treatment, on
haemodialysis,15,19 and with renal transplant.12 However, in
Argentina, despite it being known that CKD is associated
with changes that can favour the development of glycaemic
 0 1 6
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changes,9 there are few studies on the subject. In 2006,
a study19 was published that assessed only patients on
haemodialysis treatment with an OGTT, detecting new cases
of DM and IFG in 6.7% and 20%, respectively. This observa-
tion, along with the discussion opened as to whether the
assessment of such patients should follow general popula-
tion protocols or be done as a strategy to increase detection
sensitivity, encouraged us to broaden the sample to include
other stages of CKD (conservative treatment and transplant
patients).
The main contributions of this study are that the OGTT was
performed in a standardised manner, and it included patients
in 3 different stages of CKD, to detect patients whose gly-
caemic changes would have been missed if only a fasting blood
glucose sample was analysed.
The results obtained show the percentage of patients with
values consistent with DM,  according to the criteria used by
the ADA: fasting only, 3.94% (95% CI, 1.35%–6.53%); at 2 h only,
4.33% (95% CI, 1.63%–7.03%); with both criteria, 5.91% (95%
CI, 2.81%–9.00%); and at least one criteria, 14.17% (95% CI,
9.69%–18.66%), respectively.
Other authors, such as Salifu et al,15 also detected under-
diagnosis of DM,  after analysing 59 340 data from the USRDS,
detecting previously-unknown new onset DM after dialysis
(NODAD) in 7.6%. Follow-up of these patients showed a higher
3-year mortality risk than in those who did not develop DM.
Data from the Taiwan National Health Insurance Research
Database,27 with a signiﬁcant number of incident patients
(51 487), showed a cumulative incidence of new cases of DM
of 4% the ﬁrst year, reaching 21% at 9 years when taking
haemodialysis and peritoneal dialysis into account, without
signiﬁcant differences between these two modalities. Another
study,14 which evaluated the presence of DM in patients
awaiting transplant, showed an incidence of 6% and, in post-
transplant patients, an incidence of 18% to 30%, depending on
the medication given. Basturk performed an OGTT in patients
in stage 3 and 4 CKD and observed that 59.3% had IFG, 59.3%
had IGT, and 9.7% had DM.28 Another study, performed by
Ruﬁno,20 in patients with stage 4 and 5 CKD, demonstrated
that, of patients with normal fasting glucose levels, 38% had
IGT and 5% had DM:  this indicates the need to perform OGTT
to adequately diagnose all the glycaemic changes present in
these stages.
Although the majority of studies, like ours, conﬁrm the
underdiagnosis of dysglycaemia, but the methodologies are
not comparable, as the ﬁrst were performed using data
review and the last 2, which used the OGTT, used different
protocols.
The difference in prevalence of abnormal blood glucose lev-
els between fasting and post-load samples could be due to the
presence of peripheral muscular insulin resistance found in
uraemia,29 which is detected mainly by performing an OGTT.30
In addition, we  know that the 2 methods reveal patient groups
with different physiological abnormalities,31–33 which could
be present in the different CKD subgroups. Another point that
supports the use of the OGTT is that in the general population
at risk, the risk of progression to DM and the cardiovascu-
lar risk are greater if both abnormalities (IFG and IGT) are
observed simultaneously. This justiﬁes their detection, as this
information is not known in the CKD population.;3 6(2):133–140
When analysed according to type of treatment, the data
on the frequency of values consistent with DM  were different
between individuals on conventional treatment and individ-
uals on replacement therapy: 19 cases (23.45%) vs 17 cases
(9.82%) (P = .001). The same is seen with the data analysis for
the different stages of DM risk groups, where we  observe that
the frequency of impaired fasting glucose values (ADA crite-
rion) differs between treatments: 19.75% in patients treated
conservatively vs 9.24% in patients on replacement therapy
(P = .02). The frequency of IGT was also higher in those treated
conservatively (24.6% vs 20.23%), although the difference was
not statistically signiﬁcant (P = .521).
The ﬁndings of this study have different interpretations.
One interpretation is related to the fact that, the group of
patients on conservative treatment had higher body mass
index and waist measurements and more  obesity, probably
forming non-comparable groups. It must be clariﬁed that our
aim was not to compare the groups but to conﬁrm the sus-
picion that in CKD there is a large subgroup of patients in
which glycaemic changes go undetected, and consequently,
their signiﬁcance is unknown.
We must point out that there are very few publications that
study the incidence or prevalence of blood glucose values for
DM risk groups in CDK; the high prevalence observed in this
study justiﬁes their early detection. In addition, insulin resis-
tance in CKD is observed even in patients without DM and in
the early stages of CKD34,35; therefore, it could be interpreted
that the higher prevalence of glycaemic changes in the con-
servative treatment group could be attributed in some way
to this resistance. It could also be due to the pathophysiolo-
gical changes brought on by the start of replacement therapy,
when uraemia and acidosis improves, blood pressure and dys-
lipidaemia improve signiﬁcantly, and parathyroid hormone
levels decrease: these factors are known to inﬂuence insulin
secretion and the development of insulin resistance.36 Such
changes can have consequences for dysglycaemia, as has also
been demonstrated by other studies.37–39
In the multivariate analysis by multiple logistic regression,
it was observed that having values consistent with DM (by any
of the accepted criteria) was associated with the waist circum-
ference value (OR = 1.033 per cm;  95% CI, 1.005–1.062; P = .019)
and with the type of treatment (OR = 0.41; 95% CI, 0.19–0.92;
P = .028). No other variables showed signiﬁcance, probably due
to the low number in each subgroup, something that was a
limitation of this study.
The limitations of this study include the low number of
patients in each subgroup, which did not allow differentia-
tion between the changes seen in patients in stages 3, 4, and
5 on conservative treatment. In addition, only one test was
performed per patient. Another potential limitation is that
patients were not paired by weight and sex to make compar-
isons between subgroups possible.
However, the contributions of this observational study are
that it included 3 stages of CKD; there is no other study in
the references with these characteristics. Likewise, the under-
diagnosis of intermediate changes in blood glucose valuesall stages was conﬁrmed.
This study leads us to propose that, to detect all glycaemic
changes in patients with CKD, an OGTT should be performed
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n all stages of CKD and especially in patients on the transplant
aiting list. Furthermore, we propose the need to standardise
he methodology in this patient group, given that, as in other
tudies such as that by Ruﬁno,20 if the OGTT had not been per-
ormed, the presence of dysglycaemia would go undetected in
any  patients. It should be noted that the WHO18 also sug-
ests the OGTT preferentially in the general population, and
he ADA26 suggests it as an optional method with HbAlc or
asting glucose.
This alternative allows not only the early detection of dys-
lycaemia, but also starting preventative treatment to avoid
rogression from DM risk groups to DM,  as well as determin-
ng the most appropriate medication during transplantation,
nd the possibility of early access to treatment for the previ-
usly unknown new cases of DM to reduce the high morbidity
nd mortality.
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